enGene

enGene, headquartered in Vancouver, Canada, has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues, treating many prevalent and chronic diseases by inducing or suppressing protein expression levels. The company’s platform technology can significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lungs, and bladder, while also enabling protein release from the intestinal system to treat diabetes, anemia, hemophilia, and other conditions.